Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Orchard Therapeutics plc - American Depositary Shares (NQ:ORTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Orchard Therapeutics plc - American Depositary Shares

< Previous 1 2 Next >
News headline image
Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Completes ADS Ratio Change
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Announces Proposed ADS Ratio Change
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium
Four oral presentations and 11 posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
Global registrational trial expected to commence in the second half of 2023 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022
Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
News headline image
Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.